Converting from Depakote Delayed-Release to Depakote Extended-Release
When converting from Depakote DR to Depakote ER, increase the total daily dose by 8-20% and administer once daily, 12 hours after the last DR dose. This dose adjustment compensates for the lower bioavailability of the ER formulation while maintaining therapeutic valproate levels 1, 2.
Dose Conversion Strategy
The ER formulation has approximately 89% bioavailability compared to the DR formulation, necessitating a dose increase 2. Since ER tablets come in 250mg and 500mg strengths (versus DR's 125mg, 250mg, and 500mg options), practical dose increases typically range from 8-20% 1, 2.
Conversion Algorithm:
Immediate conversion (preferred method):
- Give the last dose of Depakote DR at the usual time
- Wait 12 hours
- Start Depakote ER at 8-20% higher total daily dose, given once daily 3
Example: A patient on Depakote DR 500mg twice daily (1000mg/day total) should convert to Depakote ER 1250mg once daily (25% increase, within the acceptable range given available tablet strengths).
This immediate conversion strategy causes the least perturbation in plasma valproate concentrations and maintains therapeutic levels more reliably than delayed or stepwise approaches 3.
Monitoring Requirements
Check trough valproate levels:
- Baseline level on DR formulation
- Repeat level 2 weeks after conversion to ER 4
- Monitor for clinical response and adverse effects
The ER formulation produces less fluctuation in valproate concentrations, with consistently higher trough levels and lower peak levels compared to multiple daily doses of DR 1, 2. This makes therapeutic drug monitoring more reliable, as the ER predose trough consistently represents the lowest concentration during the dosing interval 1.
Clinical Outcomes
Studies demonstrate successful conversion with maintained or improved seizure control. In one study of 41 epilepsy patients, mean seizure frequency remained essentially unchanged (3.35 seizures/month pre-conversion vs 3.29 post-conversion) 4. Additionally, some patients experienced improvements in tremor, weight gain, and gastrointestinal side effects 4, 5.
Important consideration: The 8-20% dose increase typically maintains therapeutic levels without causing toxicity. Maximum concentrations after conversion to ER are unlikely to exceed the steady-state peaks observed with the DR regimen 3.
Dosing Frequency Options
While once-daily dosing is standard and preferred for the ER formulation, twice-daily ER dosing is also acceptable if clinically indicated 4. The choice between once and twice-daily ER dosing does not significantly affect the percentage change in trough valproate levels 4.
Special Populations
For patients on enzyme-inducing medications (such as carbamazepine or phenytoin), the same conversion principles apply. The presence of enzyme-inducing agents does not alter the relative bioavailability or require different conversion strategies 4, 3.
Critical caveat: If medication residue appears in stool after conversion (rare but reported with ER formulation), check plasma valproate levels and consider alternative treatment if levels are subtherapeutic 6.